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paediatrics presented at the 2019 ERS International Congress, which was held in Madrid, Spain. The main
findings from each group are summarised at the end of each chapter.
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CONGRESS HIGHLIGHTS
PAEDIATRICS
Introduction
The Paediatric Assembly (Assembly 7) now has over 1500 members. At the European Respiratory Society
International Congress in Madrid, Spain, we came together to review the latest paediatric respiratory
research, including new data from over 350 abstracts of which half were submitted and presented by Early
Career Members. With significant input from our Early Career Members, herein we will review some of the
paediatric highlights from the Congress. We selected the most quoted abstract from each paediatric group.
Paediatric respiratory physiology and sleep
There is a suggestion that repetitive episodes of hypoxia may affect changes in bone metabolism [1, 2]. SIES
et al. [3] investigated the association of obstructive sleep apnoea (OSA) and risk of early osteoporosis in
150 children aged 1017 years. The screening tool was measuring the of speed of sound (SOS) by
quantitative ultrasound of calcaneus-achilles. It has long been known that measurement of SOS along the
length of a bone gives information about the bone density, the micro-architecture, cortical thickness and
elasticity [4]. A slower SOS means a more fragile bone. In this study, patients with OSA had a slower SOS
by quantitative ultrasound of calcaneus-achilles compared to controls suggesting risk for early
osteoporosis. Limitation of this study was that the majority of children in the OSA group were obese
which could also be a risk factor for lower vitamin D levels and hence osteoporosis.
An observational descriptive study was conducted by GHARIBZADEH HIZAL et al. [5] to assess the
sleep-related respiratory disorders in 42 children with Down syndrome at Hacettepe University (Ankara,
Turkey). OSA by polysomnography (PSG) was present in 97.6% of children in which 28.5% of them had
severe OSA. Most notable was that the majority of the families did not describe any clinical signs of sleep
disturbance.
Two abstracts presented data about alternative methods for diagnosis of OSA in children. The American
Academy of Sleep Medicine (AASM) recommends the use of oronasal thermistor and nasal cannula to
detect respiratory events and respiratory inductance plethysmography to characterise apnoeas [6].
However, nasal cannulas have a poor scorability. AMADDEO et al. [7] evaluated the use of tracheal sounds
suprasternal pressure (SSP) as an additional sensor for the detection and characterisation of respiratory
events during sleep in 17 children. They compared three methods: standard AASM signals (scoring 1);
combination of tracheal sounds and SSP with respiratory inductance plethysmography flow and oxygen
saturation measured by pulse oximetry without oronasal thermistor and nasal cannula (scoring 2); and
tracheal sounds and SSP combined with oxygen saturation measured by pulse oximetry 2 only (scoring 3).
The tracheal sounds, SSP and respiratory inductance plethysmography flow signals were present during
95%, 96% and 99% of the validated recording time, respectively, with 79% and 85% for nasal cannulas and
thermistor. Sensitivity for apnoea and hypopnoea detection was 97% and 77% (scoring 2) and 95% and
76% (scoring 3), respectively. Investigators concluded that scoring with tracheal sounds and SSP can be
used for the detection and characterisation of apnoeas in children, and may be used as an alternative.
Delta 12s, a measure of oxygen saturation variability of intervals of 12 s, has been validated for the
prediction of OSA in adults [8] and in children with Down syndrome [9] but has not been studied in
children without comorbidities. MCBRIDE et al. [10] evaluated 156 children without comorbidities, 78 were
determined to have OSA based on clinical symptoms and 19 were not. The remaining 59 were
undetermined. A delta 12s index of ⩾0.46 was shown to predict OSA with a sensitivity of 97% and
specificity of 79%. They concluded that this can be used as a simple screening test to identify children
with a high likelihood of OSA. A limitation of this study was that most of the patients did not have a
confirmation of OSA with PSG.
The last abstract is about continuous positive airway pressure (CPAP) use for OSA in children. At present
it is unclear what proportion of children can be successfully taken off CPAP and the factors that govern
this cessation. KING et al. [11] described characteristics of a cohort of 18 children on CPAP for OSA, who
were weaned off CPAP. These children had a median apnoea–hypopnoea index of 9.8 (5.7–46.0)
events·h−1 at CPAP initiation, and after a median duration of 1.0 (0.5–2.0) year, had an improvement in
median apnoea–hypopnoea index to 3.0 (1.9–4.8) events·h−1 at CPAP cessation. The reasons for CPAP
cessation included improvement post airway surgery (n=7), weight loss (n=2) and improved symptoms
and/or PSG parameters with time (n=11). In four children, CPAP therapy was ceased after initial trial due
to poor tolerance and low physician perceived clinical benefit. They concluded that children on CPAP
should be regularly screened for ongoing symptoms and need for pressure support checked as a small
group can be weaned.
In conclusion, there is a suggestion that OSA is a risk factor of early osteoporosis in children. Tracheal
sounds and suprasternal pressure are promising sensors to detect respiratory events like apnoeas. Delta
12 s, a measure of oxygen saturation, can be used as a simple screening test for OSA.
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Paediatric asthma and allergy
Several themes emerged from this year’s sessions on paediatric asthma including risk factors for asthma
development, asthma diagnosis, monitoring and management.
Maternal prenatal antibiotic use and absence of breastfeeding have been suggested as risk factors for
asthma in children [12, 13]. Two abstracts questioned these associations. Using data from Danish
registers LIU et al. [14] performed a population based cohort study, which included 411883 children.
Antibiotic use during pregnancy was found to be associated with childhood asthma in cohort
analyses, but not in sibling analyses. The authors concluded that previously observed associations may
be due to confounding factors. Similarly, a prospective cohort study of 377 unselected healthy
children from birth to 6 years by GORLANOVA et al. [15] found no association between breastfeeding
with respiratory symptoms after adjustment for confounding factors. Importantly, the authors reported
no differences in lung function or exhaled nitric oxide fraction (FeNO) between breastfed versus
non-breastfed children.
Asthma diagnosis is not straightforward, and there are no gold standard diagnostic criteria. DE JONG et al.
[16] assessed the diagnostic accuracy of symptoms and clinical tests for childhood asthma in a
cross-sectional study of 111 children. All underwent spirometry, FeNO, skin prick tests and challenge
testing by exercise, methacholine and mannitol. A positive history of wheeze, FeNO and challenge testing
by exercise emerged as having the highest combined sensitivity and specificity for asthma diagnosis in
children.
Several abstracts reported the role of FeNO in asthma monitoring. Using individual participant data from
seven studies, TURNER et al. [17] investigated the variability of FeNO in children with stable asthma over a
3-month period. In 543 children with baseline FeNO <50 parts per billion, the median (interquartile range)
absolute change and percentage change in FeNO over 3 months were +2 ppb (−4–9) and +10% (−25–66),
respectively; whilst in 131 children with a baseline FeNO of⩾50 ppb the absolute and percentage change
were −8 ppb (−28–18] and −11% (−38–32), respectively.
DIAMANT et al. [18] observed that FeNO positively correlated with severity for both day (r=0.263, p=0.003)
and night (r=0.211, p=0.021) symptoms, albeit only weakly in 125 children with abnormal baseline FeNO
(>35 ppb). LO et al. [19] conducted a cross-sectional study in 465 children with physician diagnosed or
suspected asthma. Using global lung initiative reference equations to convert absolute spirometric values
into z-scores they observed a significant but weak negative correlation between FeNO with both forced
expiratory volume in 1 s (FEV1) (r=−0.2046, p<0.0001) and FEV1/forced vital capacity (FVC) (r=−0.2042,
p<0.0001).
The recent Lancet Commission on asthma [20] highlighted the need for more personalised asthma
treatment strategies. HERNANDEZ-PACHECO et al. [21] performed a genome wide meta-analysis involving
2704 children to identify genes associated with inhaled corticosteroid response. 8.1 million genetic variants
were meta-analysed. The authors reported 19 polymorphisms associated with asthma exacerbations despite
inhaled corticosteroids (ICS) treatment. Interestingly, variants located at the CNTNAP5 gene were also
found to be associated with changes in FEV1 following ICS treatment.
Mepolizumab and omalizumab have now been approved for the treatment of severe asthma in children
from the age of 6 years across Europe. Eligibility criteria for paediatric patients are based on those for
adults. DAVIES et al. [22] investigated the eligibility criteria for either drug in a single paediatric asthma
centre. Out of 67 children, 52% were eligible for omalizumab, 80% for mepolizumab and 40% for both.
The authors concluded that in contrast to adult cohorts, a large proportion of children with severe asthma
met eligibility criteria for biologics, with significant overlap; and that paediatric-specific criteria are
urgently needed.
MURPHY et al. [23] performed a systematic review and meta-analysis on the use of oral corticosteroids
(OCS) in preschool children presenting to the emergency department with acute wheeze. Four studies
were included and OCS use was not found to reduce the risk of hospitalisation (risk ratio 0.94, 95% CI
0.8–1.12) or length of stay. The authors concluded that OCS should not be used in the emergency
department for acute preschool wheeze.
In conclusion, an association between prenatal maternal antibiotic use and absence of breast feeding
are not associated with asthma in children when confounding factors are excluded. History of wheeze,
FeNO and indirect challenge test reportedly had the best diagnostic utility for asthma diagnosis in
children. FeNO only correlates weakly with both symptoms and FEV1. However, percentage change in
FeNO may be more relevant than the absolute change. Paediatric specific criteria for biologic therapies
are urgently needed. There is still poor evidence for the use of OCS in children with acute preschool
wheeze.
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Cystic fibrosis
The changing landscape of cystic fibrosis (CF) and challenges to future care were discussed in detail
during the Congress.
The Lancet Commission was set up to address the health and economic costs over the next three decades
in order to identify how outcomes and care can be improved in this cohort of patient with the advent of
disease modifying treatment and increased numbers of adult patients. The symposium arranged by the
Commission further described four areas of collaboration [24]. First, Milan Macek spoke about the
changing epidemiology of CF. Improved genetic understanding has led to diagnosis in non-European
populations, not always presenting classically and a global initiative is currently looking at the penetrance
of over 400 known causative genes. Furthermore, due to the uptake of new-born screening (NBS),
preconception screening and improvements in care there is an ageing CF population with equal numbers
in paediatric and adult services. Secondly, Susan Madge continued this theme in describing the challenges
this will bring, with an emphasis on less invasive investigations becoming more important. She described
the need for more specialist centres and an appreciation of the multisystem nature of the disease. The
novel use of technology for self-monitoring and remote consultation also has a role to improve care. The
future in terms of symptomology with new available treatments is unclear and so personalised
management and problems of aging will be important.
Thirdly, Hector Gutierrez spoke about the challenges in building care in developing countries.
Region-specific diagnostic screening protocols are important, but in some countries incidence is so low
that NBS has not been adopted. Engaging countries and stakeholders would help to create networks, train
medical staff and enhance access to treatment. Implementation of registries and collaboration between
high performing centres and other centres is also seen as a way forward.
Finally, Marcus Mall completed the session by describing the changes in CF treatment over the years, to
the current objective of individualised CF transmembrane conductance regulator modulation. Recent
advances for patients with one or two F508 alleles using triple combination therapy were mentioned and
the strong conceptual framework for development of further therapies for all. The costs of new
medications and access to them are however a concern, pushing the need to know long-term clinical
effectiveness and transparency in costing. These advances will enable the goal of changing the diagnosis of
CF from a fatal to a treatable chronic disease.
The oral presentation session “Advances in care and monitoring of CF” reflected these issues. We heard in
the Lancet Symposium how lumacaftor/ivacaftor reduced the rate of decline and exacerbations in people with
FEV1 40–90% predicted. In this session, TONG et al. [25] presented clinical data on those with FEV1 <40%,
showing a reduced rate of exacerbations and a small increase in FEV1. However, this was complicated by a
high discontinuation rate due to treatment side-effects. Complimentary to this, MOK et al. [26] showed
quantitative computed tomography analysis (PRAGMA-CF) to be a sensitive measure of early structural
changes in CF patients on modulator treatment. COTON et al. [27] presented their meta-analysis of 61
pharmacological randomised controlled trials in patients with CF showing a small placebo response in body
mass index (BMI) but not in FEV1 or CF Questionnaire Revised-Respiratory Domain questionnaires. Finally,
OCANA et al. [28] presented work radically reducing the time to produce disease modelled personalised cells
from pluripotent stem cells from months to 3–6 weeks; a key step in the development of personalised
treatment.
Other papers in this session dealt with imaging, an area where we have seen huge advances in the last few
years. STAHL et al. [29] described disease progression in children diagnosed clinically and via NBS, and
showed the rate of exacerbations and absolute magnetic resonance imaging (MRI) scores to be lower in the
NBS group, although their rate of progression of lung disease on MRI was not reduced. SMITH et al. [30]
described advances in ventilation MRI, and demonstrated that combined xenon and proton structural MRI
was highly sensitive to changes in lung ventilation heterogeneity before spirometry and Lung Clearance
Index.
In conclusion, the evolving patient demographics, promising new and repurposed treatments along with
modalities of tracking early CF lung disease will affect the way we treat these patients and their long-term
health. The papers in this section explained these challenges and changes in more detail. These insights
will provide further evidence and inroads into meeting the aims of the Lancet Commission and improve
diagnosis and treatment of CF worldwide.
Paediatric respiratory infection and immunology
The presentations at 2019 European Respiratory Society Congress covered many aspects of paediatric
respiratory infections. In particular, with regard to asthma and wheezing prevention strategies, the study
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by HARVEY et al. [31] demonstrated that in infants born to mothers with asthma, breastfeeding for at least
6 months was protective for wheeze, but not for bronchiolitis.
Two studies focused on protracted bacterial bronchitis (PBB). One by LAIRD et al. [32] investigated the
prevalence of PBB in children from four remote communities of Western Australia. They found a chronic
wet cough in 21 out of 191 children and a PBB prevalence of 10% (95% CI 6–16%). The other study by
GROSE-HODGE et al. [33] found that recurrence of PBB was significantly lower in children treated with a
6 weeks course of antibiotics compared to ⩽4 weeks course, suggesting a possible need to change the
international guidelines for the PBB treatment.
Concerning “hospital in the home” intravenous antibiotic treatment of respiratory exacerbation in children
with bronchiectasis, O’ROURKE et al. [34] found no difference in the therapy duration, effectiveness and
time to the next exacerbation when compared to hospital-based treatment.
As regards the genetic analysis of primary ciliary dyskinesia, in a Danish cohort of affected children,
MARTHIN et al. [35] reported that mutations in CCDC40 were more frequent than mutations in DNAH5
and half of patients with these two mutations were diagnosed after 5 years of age and almost 10% of
patients had normal nasal nitric oxide.
A hot topic of this session was the airway microbiota. DE KOFF et al. [36] found that in infants hospitalised
for a lower respiratory tract infection, the occurrence of re-infection within 4–8 weeks was associated with
younger age, antibiotic treatment, wheezing disease phenotype and an abundance of gram-negative
bacteria in the nasopharyngeal microbiota. MAN et al. [37] compared the oral microbiota to the
nasopharyngeal microbiota longitudinally in infants aged <6 months of age. They found that oral
microbiota may induce changes in the nasopharyngeal microbiota prior to a respiratory infection
especially in infants attending daycare. The abstract by CLERC et al. [38] suggested that there is a link
between the oral, nasopharyngeal and intestinal microbiota and the presence of a stable microbiome
network architecture is associated with respiratory health in infants up to 6 months of age.
Bronchiolitis and microbiota was one of the most discussed topic. The abstract by MULHOLLAND et al. [39]
demonstrated that, in infants hospitalised in paediatric intensive care units for bronchiolitis, the upper
airway microbiota was similar to the lower airway microbiota. PERSIA et al. [40] demonstrated that in
respiratory syncytial virus (RSV) bronchiolitis the nasopharyngeal microbiota have a reduced alfa-diversity
compared to virus negative infants with bronchiolitis. The microbiota composition also differed between
the genotype A and B of the RSV. This study showed that there is a strict correlation between microbiota
composition and viral infection, however it still remains unclear if changes in the microbiota occur first or
are caused by the virus.
CONEJERO et al. [41] reported the results of a trial with a sublingual polybacterial immunotherapy
(MV130). 6 months of therapy reduced the number and duration of wheezing episodes children. In an in
vitro model, the MV130 proved to be effective in training innate immune cells and in reducing viral
infections.
In the field of RSV infection, XU et al. [42] reported new results of the MAKI trial. The use of palivizumab
in preterm infants significantly lowered the DNA methylation in the nasal epithelium at the age of 6 years,
suggesting that RSV infection in infancy has long-term effect on epigenetics.
Regarding bronchiolitis from RSV, PIERANGELI et al. [43] reported the phylogenetic analysis of the G gene
of the RSV-A ON1. In RSV-A ON1 genotype several aminoacidic changes occurred over time in the
hypervariable regions. In particular, during the 2017–2018 season, these aminoacidic changes appeared in
sites never reported before and were associated with a worse clinical disease course.
NENNA et al. [44] reported that in infants hospitalised for RSV bronchiolitis, viral factors (higher viral load,
RSV genotype NA1) are associated with occurrence of recurrent wheezing after 3 years of follow-up in
combination with host factors (exposure to smoking, family history of asthma and feeding with formula).
The Paediatric Respiratory Infection and Immunology section covered a lot of different topics. In
particular it has been reported that breastfeeding is a protective factor for recurrent wheezing, while after
RSV bronchiolitis the recurrence of wheezing is higher in infants that were infected with the RSV-ON1
genotype. Upper and lower respiratory microbiota are linked and their changes are associated with
recurrence of respiratory infections and RSV bronchiolitis, while a stable network between the
nasopharyngeal, the oral and the intestinal microbiota is associated with respiratory health in infants.
Neonatology and paediatric intensive care
Advances in neonatal pulmonology are rapidly developing as more infants are surviving being born
prematurely. Novel techniques to assess long-term lung function alongside determining underlying disease
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mechanisms are promising research areas and thereby allow us to better understand and target respiratory
complications of preterm birth.
HARRIS et al. [45] described a cluster analysis approach of the neonatal population. Innovative methods
allow identification of multidimensional subgroups to further inform specific treatments. A cohort of 330
prematurely born infants was followed up to adolescence and a predictive algorithm was derived from
decision tree analysis. Four main clusters were identified with superior lung function seen in those infants
who received high frequency oscillation in the neonatal period. The other three clusters included infants
born at a lower gestational age and with a higher incidence of bronchopulmonary pulmonary dysplasia.
However, there was no difference in lung function concerning the two modes of respiratory support
received.
LUNDBERG et al. [46] described the challenges faced by young children born prematurely, specifically in
performing lung function tests at follow-up, with impulse oscillometry reported to be easier to perform
[47]. The authors evaluated the feasibility of performance between the widely used dynamic spirometry
and impulse oscillometry in 6-year-old children. Preterm infants experienced similar difficulties in
spirometry as term infants, and there was strong coherence between the results of both techniques within
the group of preterm infants. A pilot study by GUERRA AZEVEDO et al. [48] evaluated the application of a
three-dimensional kinematic model for predicting tidal volumes. This novel method of VT estimation by
kinematic analysis was comparable to standard predicting measures of VT per kilogram of body weight.
Prematurely born infants in early postnatal life exhibit a blunted hypoxic ventilatory response [49].
SIMPSON et al. [50] assessed preterm infants at 12–15 months of corrected postnatal age to establish
whether the response was developed at this age. Interestingly, male infants (p=0.009) and those with an
increased duration of supplemental oxygen exposure (p=0.026) still had a diminished response. Prolonged
supplemental oxygen exposure in the neonatal period renders preterm infants susceptible to adverse
outcomes such as retinopathy of prematurity and bronchopulmonary dysplasia (BPD) [51]; however, the
shared molecular pathways underlying these two entities remains unknown. WICKRAMASINGHE et al. [52]
utilised an animal model previously used to assess retinopathy of prematurity to study the development of
chronic lung disease. Histopathology specimens of the lung and retina of neonatal mice exposed to
hyperoxia were examined and compared to room-air controls. Their results showed alveolar wall
thickening in combination with retinal vascular degeneration in the mice exposed to supplemental oxygen.
This novel model gives us an insight into future developments of targeting a single therapy to ameliorate
both pulmonary and retinal tissue damage.
Recent evidence has shown a reduction in the composite outcome of BPD or all-cause mortality in
preterm infants treated with caffeine citrate [53]; however, the mechanism of action is complex and not
fully understood. Two abstracts described the effect of caffeine therapy on pulmonary function in preterm
infants. BARBERO et al. [54] performed rapid thoracoabdominal compression to assess lung function.
Multivariate analysis showed that FVC and FEV0.5 were higher in the cohort of preterm infants receiving
caffeine. WILLIAMS et al. [55] investigated the effect of caffeine on the electrical activity of the diaphragm in
ventilated preterm infants. The authors found a significant increase in the amplitude of the electrical
activity of the diaphragm, which peaked at 25 min post-caffeine administration (p=0.006) and was
associated with an improvement in respiratory function. Prediction of extubation outcome remains a
challenge in neonatal respiratory medicine with extubation failure rate at 33% [56]. Noninvasive
monitoring of the electrical activity of the diaphragm can be used to assess neural respiratory drive [57].
HUNT et al. [58] aimed to determine the predictive ability of surface electromyography in extubation
outcome. This method was tested in a cohort of 72 infants using the area under the receiver-operator
characteristic curve to predict extubation success. However, it was shown that clinical variables remained
better predictors of extubation success than diaphragmatic electrical activity (AUC=0.55) with weight at
study being the best predictor (AUC=0.81).
Novel and promising methodologies were described, such as a shared histopathological animal model for
BPD and retinopathy of prematurity, diaphragmatic surface electromyography and lung function following
thoracoabdominal compression. Ex-preterm infants exhibit significant persisting pathology such as
reduced hypoxic responses and poorer lung function in childhood. Prediction of extubation remains
evasive as clinical variables are superior to surface diaphragmatic electromyography. A novel
three-dimensional kinematic model was found to accurately predict tidal volumes and impulse
oscillometry is a feasible modality of lung function measurement in ex-preterm infants at follow-up.
Paediatric respiratory epidemiology
The importance of early life environment and the development of respiratory diseases later in life is now
one of the most important and frequently studied topics in respiratory research. Starting with intrauterine
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exposures, LUNDHOLM et al. [59] found that: 1) the association between prenatal exposure to smoking and
asthma in the offspring was strongest in the early years (5 and 18 months, moments when mother-infant
activities or day care is usually started); 2) it was weaker when studying oral moist snuff with high nicotine
content (therefore not due to nicotine); and 3) the effect was not present in the sibling comparison
analysis (suggesting shared familial factors such as passive smoking). ABELLAN et al. [60] used data from
2685 mother-child pairs from eight European birth cohorts to show that bisphenol-A (BPA) exposure was
detected in 79% of mothers during pregnancy, with a much lower exposure to other phenols, and that
increasing prenatal BPA exposure tended to be associated with lower lung function (FVC and FEV1) and
increased odds of wheeze or asthma at 6 and 10 years of age. However, these results were not adjusted for
breastfeeding, birthweight or postnatal phenol exposure.
The role of obesity on asthma development has not yet been well elucidated. Using cross-sectional data
from the population-based Generation R cohort, MENSINK-BOUT et al. [61] found that both general fat and
organ fat were associated with airway obstruction in lung function (increased FVC with decreased FEV1/
FVC), while only organ fat, independent of total fat mass, was associated with reported
physician-diagnosed asthma. PERALTA et al. [62] used data from the population-based INMA birth cohort
study to show that, independent from departing birth size, children with accelerated BMI gain during the
first years of life had lower FEV1/FVC ratio and higher FVC at school age, opposite to what occurred to
those with lower birth size and slow BMI gain.
Long-term morbidity prediction and natural history of asthma are also research areas of interest. LONGO
et al. [63] studied the long-term adverse outcomes of poor asthma control, and found that pre-schoolers
with suboptimal asthma control in the 2 years following diagnosis from a Canadian birth cohort, had a
higher risk of long-term poor control. In Sweden, OSVALD et al. [64] reported that even though the rate of
death from asthma is low in children and young adults (1–25 years), asthma increased the risk of all-cause
mortality. The presence of life-limiting conditions modified this effect by increasing the risk.
Finally, an ecological study in the UK by WALKER et al. [65], showed that English regions with a higher
number of annual hours of sunlight had lower annual lower respiratory tract infection admission rates. It
is now necessary to assess if this association is explained by a possible vitamin D deficiency.
The influence of early life environment in lung health later in life is becoming clearer, as shown with the
negative impact of prenatal tobacco smoke and BPA exposure. Accelerated BMI gain in infants may affect
lung function at school age, while organ fat and not total fat mass was associated with a doctor’s asthma
diagnosis in children. Pre-schoolers with a suboptimal asthma control may have a poorer control in the long
term, and asthma in children and young adults seems to increase all-cause mortality. In an ecological study,
increased hours of sunshine was associated with reduced admissions for lower respiratory tract infections.
Paediatric bronchology
In the poster discussion session “ a mixture of rare lung diseases”, the discussion showed recent advances
in primary ciliary dyskinesia (PCD), interstitial lung disease in children and respiratory and sleep
physiology that ranged from diagnostic and therapeutic interventions to the search for follow-up
interventions and predictors to optimised care and prognosis.
AMIGO et al. [66] evaluated 51 patients with high clinical suspicion of PCD and concluded, that the
combination of high-speed video-microscopy and immnunofluorescence can lead to the diagnosis in many
cases. Another study of immnunofluorescence examination in 36 PCD suspected patients by ATAG et al.
[67] revealed ciliary defects in 83% of patients. Authors emphasised the power of immnunofluorescence in
the diagnosis of PCD. CHATZIPARASIDIS et al. [68] retrospectively analysed medical records of 235 patients
referred to Athens PCD Centre with a suspicion of PCD on the basis of medical history. Unfortunately
referral accuracy was low; 59.3% of referred patients scored <5 PICADAR points (cut-off score).
EMIRALIOĞLU et al. [69] showed in a cohort of 46 Turkish patients with PCD that subjects with CCNO
mutations are diagnosed earlier and those with CCDC40 or CCNO mutations had more severe lung
disease and poorer nutritional status. CORULLÓN et al. [70] focused on psychological functioning of patients
with PCD. 41.9% of the subjects presented with anxiety and 16.7% with depression with a tendency to
underestimate the threat of the disease.
In a retrospective study, FERRARO et al. [71] analysed airway to artery dimensions and the number of
visible airways on chest computed tomography of 13 PCD patients. The authors showed that in PCD
airways are more dilated compared to healthy controls.
PORCARO et al. [72] presented results of retrospective data analysis of 132 non-CF patients with diagnosis
of bronchiectasis. Recurrent infections were the most common cause of bronchiectasis and chronic cough
was the most common symptom at first evaluation.
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AINSWORTH et al. [73] characterised the airway microbiota by collecting nasal swabs and sputum samples of
28 children with bronchiectasis at the time of acute exacerbations and after treatment.
COST action 16125 “Enter-ChILD” WG6 assessed the registry-based capacity for identifying interstitial
lung disease in children (chILD) and young adults across Europe. Authors identified several national, local
and one international database. Many chILD conditions can be aggregated across identified databases and
can help researchers to create cohorts for clinical trials [74]. CARLENS et al. [75] performed retrospective
analysis and prospective follow-up of five cases with TBX4 mutation. Patients presented with different
severity and progression of respiratory disease: three children required pulmonary hypertension treatment,
three required oxygen supplementation, and one had lung transplantation at last follow-up. RING et al. [76]
performed a cross-sectional study of 31 chILD patients and aimed to utilise the hypoxic challenge test
(HCT) as a surrogate assessment of inflight saturation. Desaturation <90% occurred in 35% of patients
during HCT without any relationship to lung function. HCT test should be considered in all children with
diffuse lung disease despite normal lung function parameters and normal room air saturation.
MARCZAK et al. [77] prospectively assessed pulmonary function in 25 children aged >4 years diagnosed
with persistent tachypnoea of infancy. In most patients with persistent tachypnoea of infancy,
abnormalities in pulmonary function tests were observed. Air trapping and high airways resistance were
common findings and ventilation heterogeneity was observed in the majority of them.
PARISI et al. [78] evaluated Lung Clearance Index results of 57 off-treatment childhood cancer survivors
and 50 age-matched healthy controls and did not find any differences in lung function between groups.
GROSE-HODGE et al. [79] retrospectively investigated incidence of post-procedure complications of 155
paediatric flexible bronchoscopies with bronchoalveolar lavage. In this cohort, 8% of children experienced
side-effects that led to discharge delay or re-admission to the hospital. SCHRAMM et al. [80] conducted an
international study and analysed 446 foreign body removals. Overall, severe complications occurred in 1%
of all rigid procedures and in 0.8% of the flexible. ELDERS et al. [81] performed static and dynamic MRI
studies of 48 patients who underwent open airway surgery for laryngotracheal stenosis. According to the
authors, MRI is a suitable method for evaluation of structure and function of the upper airway in post
laryngotracheal stenosis children.
In conclusion, immnunofluorescence can be crucial in the diagnosis of PCD. Particular mutation in PCD
can predict severity of lung disease and nutritional status. Recurrent infections are the most common
cause of bronchiectasis and chronic cough is the most common symptom at first evaluation. Hypoxic
challenge test should be considered in all children with diffuse lung disease despite normal lung function
parameters and normal room air saturation. In most patients with persistent tachypnoea of infancy,
abnormalities in pulmonary function tests are observed.
Lung and airway developmental biology
The session comprised of seven oral presentations. Five presentations covered the field of basic lung
research. Two presentations were clinical studies.
In their late breaking abstract, KUCHIBHOTLA et al. [82] hypothesised that in the asthmatic airway, increased
β-catenin signalling activates Notch resulting in increased differentiation of mucous cell in the airway
epithelium. Using an in vitro model of asthmatic and healthy airway epithelium (primary bronchial
epithelial cell) in an air–liquid interface culture, they did not observe significant changes in mRNA
expression of β-catenin, Notch and their respective targets. This was confirmed by immunohistochemistry
results. Furthermore, differentiation markers FOXJ1, FOXA2 and MUC5AC were not changed. Gain- and
loss-of-function experiments of β-catenin and/or Notch signalling pathways in healthy primary bronchial
epithelial cell are planned. The better understanding of mucous cell differentiation might open new
therapeutic avenues.
In turn, ISAGO et al. [83] presented data implicating a role of transcriptional co-activator with PDZ-binding
motif (TAZ) and Yes-associated protein (YAP) in controlling lung development at different stages by using
conditional KO mice for TAZ and YAP. In addition, the results suggested the existence of a novel pathway
between transforming growth factor-β and Shh.
The research group of Alejandre Alcazar identified a novel KLF4-SMAD2-STAT3 axis being potentially
responsible for lung regeneration in a mouse model of BPD. In detail, reduced ATII markers after
hyperoxia were associated with reduced KLF4 expression and lung growth. This was confirmed by in vitro
data using KLF4 gain-of-function and loss-of-function in MLE12 cells [84]. Another study from his group
investigated the impact of maternal obesity on lung microvessels in the offspring. Indeed, maternal obesity
led to increased levels of interleukin (IL)-6 and increased the risk of developing pulmonary arterial
hypertension. They showed that IL-6-induced phosphorylation of STAT3, which sequestered FOXO1 in
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the cytoplasm. Using IL-6-/- mice they identified an IL-6-FOXO1 mediated hyperplasia of vascular
smooth muscle cells which could be prevented by a FOXO1 activator (Paclitaxel) [85].
GIE et al. [86] aimed to characterise the effects of intermittent CPAP on lung function and structure in a
preterm rabbit model of BPD. Lung function tests and analyses on alveolar, vascular and airway
morphology revealed that hyperoxia significantly altered lung function and morphology. However, CPAP
attenuated the functional and structural changes of hyperoxic lung injury.
A study by HAGMAN et al. [87] focused on the lung function of prematurely born infants (median 27 weeks
of gestational age and birth weight 950 g) at 12 years of age, compared with infants born at term. Using
spirometry, impulse oscillometry, body plethysmography and diffusing capacity they showed that preterm
birth is associated with an increased risk for obstructive airway disease and impaired lung function. This
observation was independent of suffering from BPD or not.
The study of HERMELIJN et al. [88] aimed to establish a clinical guide for systemic assessment of computed
tomography imaging in congenital lung abnormalities. Based on an extensive literature search they
suggested an uniform nomenclature and the use of objective radiologic features for the description of
congenital lung abnormalities.
In conclusion, β-catenin signalling activates Notch resulting in increased differentiation of mucous cell in
the airway epithelium. Transcriptional co-activator with PDZ-binding motif and Yes-associated protein are
involved in controlling lung development at different stages. Novel KLF4-SMAD2-STAT3 axis might be
responsible for lung regeneration in a mouse model of BPD. Maternal obesity leads to increased levels of
IL-6 and increased risk of developing pulmonary arterial hypertension through IL-6-FOXO1 mediated
hyperplasia of vascular smooth muscle cells. CPAP attenuates the functional and structural changes of
hyperoxic lung injury in a BPD rabbit model. Preterm birth is associated with an increased risk for
obstructive airway disease and impaired lung function, independent of suffering from BPD or not.
Objective radiologic features are needed for systemic assessment of computed tomography imaging in
congenital lung abnormalities.
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